参考文献/References:
[1]姚路红,张军.SGLT2抑制剂在老年糖尿病人群中应用的相关研究[J].中国循证心血管医学杂志,2012,13(7):895-896.[2]李洪梅,朱海清.中国糖尿病肾脏病防治指南(2021年版)解读[J].中国医刊,2022,57(2):133-138.[3]Bonner R,Albajrami O,Hudspeth J,et al.Diabetic Kidney Disease[J].Prim Care,2020,47(4):645-659.[4]Prandi FR,Barone L,Lecis D,et al.Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors[J].Biomolecules,2022,12(10):1349.[5]Erraez S,López-Mesa M,Gómez-Fernández P.Mineralcorticoid receptor blockers in chronic kidney disease[J].Nefrologia (Engl Ed).2021,41(3):258-275.[6]曹晔,杨丹,苏津,等.糖尿病肾病患者肾素－血管紧张素－醛固酮系统与血流动力学的关系[J].临床检验杂志,2012,12(22):1004-1005．[7]]Lin YC,Chang YH,Yang SY,et al.Update of pathophysiology and management of diabetic kidney disease[J].J Formos Med Assoc,2018,117(8):662-675.[8]Greco EV,Russo G,Giandalia A,et al.GLP-1 Receptor Agonists and Kidney Protection[J].Medicina (Kaunas),2019,55(6):233.[9]Tan C,Gu J,Li T,et al.Inhibition of aerobic glycolysis alleviates sepsis induced acute kidney injury by promoting lactate/Sirtuin 3/AMPK regulated autophagy[J].Int J Mol Med,2021,47(3):19.[10]Jigheh ZA,Haghjo AG,Argani H,et al.Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis[J].Iran J Basic Med Sci,2019,22(4):384-390.[11]Pichler R,Afkarian M,Dieter BP,et al.Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets[J].Am J Physiol Renal Physiol,2017,312(4):F716-F731.[12]Li X,Lu L,Hou W,et al.Epigenetics in the pathogenesis of diabetic nephropathy[J].Acta Biochim Biophys Sin (Shanghai),2022,54(2):163-172.[13]Lu Q,Zhou Y,Hao M,et al.The mTOR promotes oxidative stress- induced apoptosis of mesangial cells in diabetic nephropathy[J].Mol Cell Endocrinol,2018,473:31-43.[14]Barati MT,Merchant ML,Kain AB,et al.Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice[J].Am J Physiol Renal Physiol,2007,293:F1157–F1165.[15]吕玲.葡萄糖目标范围内时间与2型糖尿病肾脏疾病的相关性研究[D].长春:吉林大学,2022.[16]Tuttle KR,Agarwal R,Alpers CE,et al.Molecular mechanisms and therapeutic targets for diabetic kidney disease[J].Kidney Int,2022,102(2):248-260.[17]Koch EAT,Nakhoul R,Nakhoul F,et al.Autophagy in diabetic nephropathy: a review[J].Int Urol Nephrol,2020,52(9):1705-1712.[18]Bermejo S,García CO,Rodríguez E,et al.The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease[J].Nefrologia (Engl Ed),2018,38(2):197-206.[19]莫一菲,包玉倩.《中国血糖监测临床应用指南(2021年版)》解读[J]．中华糖尿病杂志,2021,13(10):926-929.[20]Advani A.Positioning time in range in diabetes management[J].Diabetologia,2020,63(2):242-252.[21]Beck RW,Bergenstal RM,Cheng P,et al.The Relationships Between Time in Range,Hyperglycemia Metrics,and HbA1c[J].J Diabetes Sci Technol,2019,13(4):614-626.[22]Kalra S,Shaikh S,Priya G,et al.Correction to: Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel[J].Diabetes Ther,2021,12(9):2627-2629.[23]Runge AS,Kennedy L,Brown AS,et al.Does Time-in-Range Matter Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes[J].Clin Diabetes,2018,36(2):112-119.[24]Vigersky RA,McMahon C.The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes[J].Diabetes Technol Ther,2019,21(2):81-85.[25]陆菊明.葡萄糖目标范围内时间:从指南角度看血糖达标[J].药品评价,2021,18(9):513-515.[26]Barrera-Chimal J,Jaisser F.Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets[J].Diabetes Obes Metab,2020,22 Suppl 1:16-31. [27]Beck RW,Bergenstal RM,Riddlesworth TD,et al.Validation of time in range as an outcome measure for diabetes clinical trials[J].Diabetes Care,2019,42(3):400-405.[28]Yoo JH,Choi MS,Ahn J,et al.Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes[J].Diabetes Technol Ther,2020,22(10):768-776.[29]Lu J,Ma X,Zhou J,et al.Association of Time in Range,as Assessed by Continuous Glucose Monitoring,With Diabetic Retinopathy in Type 2 Diabetes[J].Diabetes Care,2018,41(11):2370-2376.[30]Sheng X,Xiong GH,Yu PF,et al.The Correlation between Time in Range and Diabetic Microvascular Complications Utilizing Information Management Platform[J].Int J Endocrinol,2020,2020:8879085.
相似文献/References:
[1]田盼盼,张惠莉.血糖波动的研究概况[J].医学信息,2020,33(20):34.[doi:10.3969/j.issn.1006-1959.2020.20.010]
TIAN Pan-pan,ZHANG Hui-li.Research Overview of Blood Glucose Fluctuation[J].Journal of Medical Information,2020,33(13):34.[doi:10.3969/j.issn.1006-1959.2020.20.010]
[2]龙丹凤,徐志伟,王小芳,等.2型糖尿病并发症流行病学调查及危险因素[J].医学信息,2020,33(21):128.[doi:10.3969/j.issn.1006-1959.2020.21.039]
LONG Dan-feng,XU Zhi-wei,WANG Xiao-fang,et al.Epidemiological Investigation and Risk Factors of Type 2 Diabetes Complications[J].Journal of Medical Information,2020,33(13):128.[doi:10.3969/j.issn.1006-1959.2020.21.039]
[3]于芳宁,张 宁.基于CiteSpace的近十年我国针灸治疗糖尿病相关研究的文献可视化分析[J].医学信息,2022,35(05):11.[doi:10.3969/j.issn.1006-1959.2022.05.003]
YU Fang-ning,ZHANG Ning.Visualized Analysis of Domestic Research Hotspot and Trend of Acupuncture and Moxibustion Treatment of Diabetes Mellitus in Recent Ten Years Based on CiteSpace[J].Journal of Medical Information,2022,35(13):11.[doi:10.3969/j.issn.1006-1959.2022.05.003]
[4]蔡佩珊,陈玉华,林铭旭.葡萄糖目标范围内时间在2型糖尿病慢性并发症中的研究现状[J].医学信息,2023,36(18):175.[doi:10.3969/j.issn.1006-1959.2023.18.036]
CAI Pei-shan,CHEN Yu-hua,LIN Ming-xu.Research Status of Time in Range in Chronic Complications of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2023,36(13):175.[doi:10.3969/j.issn.1006-1959.2023.18.036]